Search
Disoxaril
go.drugbank.com/drugs/DB08726Experimental5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. … Known drug targets of 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole include genome polyprotein.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 3-METHYL-5-(7-(P-2-OXAZOLIN-2-YLPHENOXY)HEPTYL)ISOXAZOLE, 5-(7-(4-(4,5-dihydro-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazoleNinvosudil
go.drugbank.com/drugs/DB08756InvestigationalY-27632 is an inhibitor of Rho-associated protein kinase. It inhibits calcium sensitization to affect smooth muscle relaxation.
Categories: Heterocyclic Compounds, 1-RingSynonyms: (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide, 4-[(1R)-1-aminoethyl]-N-(pyridin-4-yl)cyclohexane-1-carboxamideNandrolone decanoate
go.drugbank.com/drugs/DB08804ApprovedIllicitInvestigational[A233849] Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564] … [A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: PARABOLIN RETARD 5 MG AMPUL, 2 ADET, DECA - DURABOLIN® 50 MGLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalLurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the t...
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: LURAP® 40, LURAP ® 80Lomitapide
go.drugbank.com/drugs/DB08827Approved[A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity. … Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP).
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A InhibitorsSynonyms: 9H-FLUORENE-9-CARBOXAMIDE, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)-1-PIPERIDINYL)BUTYL)-, N-(2,2,2-TRIFLUOROETHYL)-9-(4-(4-(((4'-(TRIFLUOROMETHYL)BIPHENYL-2-YL)CARBONYL)AMINO)PIPERIDIN-1-YL)BUTYL)-9H-FLUORENE-9-CARBOXAMIDETemocapril
go.drugbank.com/drugs/DB08836InvestigationalTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.
Categories: Heterocyclic Compounds, 1-RingRilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative. … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's
Mixtures: ODEFSEY® 200 MG - 25 MG - 25 MG TABLETAS RECUBIERTAS, Odefsey® (200mg Emtricitabine/25mg Rilpivirine/25mg Tenofovir alafenamide) film coated tabletsCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEribulin
go.drugbank.com/drugs/DB08871ApprovedInvestigationalEribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic
Categories: Heterocyclic Compounds, 1-RingRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVI 5 MG (TABLETS), JAKAVI® 10MG TABLETASLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist. … [A260276] It is also a homolog of a heat-stable enterotoxin derived from _Escherichia coli_, the first natural ligand that activates GC-C.
Categories: Guanylate Cyclase-C Agonist, Guanylyl Cyclase C AgonistsSynonyms: -GLUTAMYL-L-TYROSYL-L-CYSTEINYL-L-CYSTEINYL-L-ASPARAGINYL-L-PROLYL-L-ALANYL-L-CYSTEINYL-L-THREONYLGLYCYL-L-CYSTEINYL-, CYCLIC (1->6),(2->10),(5->13)-TRIS(DISULFIDE), L-TYROSINE, L-CYSTEINYL-L-CYSTEINYL-L-.ALPHA.